fampyra
biogen netherlands b.v. - fampridine - sklerosi multipla - drogi oħra tas-sistema nervuża - fampyra huwa indikat għat-titjib tal-mixi f'pazjenti adulti bi sklerożi multipla b'diżabilità fil-mixi (skala ta 'status ta' diżabilità espandut 4-7).
human igg1 monoclonal antibody specific for human interleukin-1 alpha xbiotech
xbiotech germany gmbh - antikorp monoklonali uman igg1 speċifiku għal interleukin-1 alfa tal-bniedem - neoplażmi kolorettali - aġenti antineoplastiċi - it-trattament tal-kanċer metastatiku tal-kolorektum.
tecfidera
biogen netherlands b.v. - dimetil fumarate - sklerosi multipla - immunosoppressanti - tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).
plegridy
biogen netherlands b.v. - peginterferon beta-1a - sklerosi multipla - immunostimulanti, - kura ta 'sklerożi multipla li tirkadi ta' ripetizzjoni f'pazjenti adulti.
spinraza
biogen netherlands b.v. - nusinersen sodium - atrofija muskolari, spinali - drogi oħra tas-sistema nervuża - spinraza hija indikata għat-trattament ta '5q atrofija muskolari spinali.
zinbryta
biogen idec ltd - daclizumab - sklerosi multipla - immunosoppressanti - zinbryta huwa indikat f'pazjenti adulti għat-trattament ta 'forom ta' sklerożi multipla li tirkadi (rms).
vumerity
biogen netherlands b.v. - diroximel fumarate (biib098) - l-isklerożi multipla, sklerożi multipla li tirkadi u tbatti - immunosoppressanti - vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see section 5. 1 for important information on the populations for which efficacy has been established).
neupopeg
dompé biotec s.p.a. - pegfilgrastim - neutropenia; cancer - immunostimulanti, - tnaqqis fit-tul tal-neutropenia u l-inċidenza tal-marda bid-deni neutropenia fil-pazjenti trattati ma chemotherapy ċitotossiċi għall-malignancy (bl-eċċezzjoni ta ' kronika myeloid lewċemja u myelodysplastic sindromi).
tysabri
biogen netherlands b.v. - natalizumab - sklerosi multipla - immunosuppressanti selettivi - tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups: , patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 u 5. 1), , or, patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain mri or a significant increase in t2 lesion load as compared to a previous recent mri.
nespo
dompé biotec s.p.a. - darbepoetin alfa - kidney failure, chronic; anemia; cancer - preparazzjonijiet antianemiċi - kura ta 'anemija sintomatika assoċjata ma' insuffiċjenza renali kronika (crf) f'adulti u pazjenti pedjatriċi. kura ta ' anemija sintomatika f'pazjenti adulti bil-kanċer tumuri malinni mhux majelojdi li qed jirċievu l-kimoterapija.